TerminatedPhase 2

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Stopped: Slow Accrual

United States12 participantsStarted 2015-06-11

Plain-language summary

This randomized phase II trial studies how well lenalidomide improves immune response to pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or monoclonal B cell lymphocytosis. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Lenalidomide may also improve the effectiveness of pneumococcal 13-valent conjugate vaccine that is used to prevent infection.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. CLL according to the National Cancer Institute (NCI) criteria
✓. Small lymphocytic lymphoma (SLL) according to the World Health Organization (WHO) criteria
✓. MBL according to the consensus criteria

What they're measuring

Proportion of Participants With Successful Response

Timeframe: Day 43

Trial details

NCT IDNCT02309515

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-04-28

Results submitted2019-12-31

View on ClinicalTrials.gov More Monoclonal B-Cell Lymphocytosis trials